GlassScriptPhysician profile
Abigail Connor
NPI 1265202071
$5,970.07
in general payments reported to CMS, 2019-2025
25 companies · $3,379 in 2025
The $3,379 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.81 · 2024: $2,574 · 2025: $3,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,668 · Consulting Fee: $170 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,667.98 |
| Consulting Fee | $170.10 |
| Education | $131.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,219.18 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,031.73 | 2024-2025 | |
| Glaxosmithkline, LLC. | $709.86 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $666.57 | 2024-2025 | Tezspire, Actimmune |
| Grifols USA, LLC | $555.25 | 2024-2025 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $190.06 | 2024-2025 | |
| Adma Biomanufacturing LLC | $170.10 | 2024-2025 | |
| Octapharma USA, INC. | $152.91 | 2024-2025 | Cutaquig, Octagam Immune Globulin (Human), Panzyga |
| Optinose US, INC. | $141.87 | 2024-2025 | |
| Abbvie INC. | $138.53 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.04 | 2024-2025 | Cuvitru, Hyqvia |
| Biocryst US Sales Co., LLC | $115.46 | 2024-2025 | Orladeyo |
| Csl Behring | $107.39 | 2023-2025 | Hizentra |
| Pfizer INC. | $105.61 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $97.99 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $88.33 | 2024-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $73.63 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $64.42 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $62.70 | 2025 | Ohtuvayre |
| Leo Pharma INC. | $37.50 | 2024-2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $27.43 | 2025 | Nemluvio |
| Greer Laboratories, INC. | $23.64 | 2025 | Oralair |
| Pharming Healthcare, INC. | $20.99 | 2025 | Ruconest |
| Invivyd INC | $17.71 | 2025 | Pemgarda |
| Azurity Pharmaceuticals, INC. | $16.17 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.